Hint mode is switched on Switch off
For swift navigation between sections

Artgen Biotech
TIN 7702508905, PSRN 1037789001315

PDF download

Choose all Reset all
Download Cancel
Organization name
PJSC "Artgen Biotech"
Country name
Russia
Country of registration
Russia
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
  • ACRA / Expert RA
    *** / -
Public debt
8 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Artgen Biotech is a Russian public biotech company which is engaged in drug discovery, R&D and marketing of innovative proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy and biopharmaceutics.

Awards

News

30/07/2021 Human Stem Cell Institute announces about increased RAS net profit for 6 months of 2021 equal to RUB 60.07 million. Total revenue’s increase is 33.88%
06/04/2021 RAS. Human Stem Cell Institute. December 31, 2020: long-term liabilities’ increase is 5.11 % YoY
05/06/2020 Rusgrain Holding’s, Human Stem Cell Institute’s 1 Q 2020 Y RAS results were published
22/07/2019 First Collection Bureau’s, ALROSA-Nurba’s, Human Stem Cell Institute’s RAS results were published
All organization news

Documentation

IFRS/US GAAP reports

2025
II q NTL
IV q NTL
2024
II q NTL
IV q NTL
2023
II q NTL
IV q NTL
2022
II q NTL
IV q NTL
2021
II q NTL
IV q NTL
2020
II q NTL
IV q NTL
2019
II q NTL
IV q NTL
2018
II q NTL
IV q NTL
2017
I q NTL
II q NTL
III q NTL
IV q NTL
2016
II q NTL
III q NTL
IV q NTL
2015
II q NTL
IV q NTL
Show all Hide
Authorization required
You need to request access

Affiliates

Show more Hide

Stocks

Related entities on 03/09/2023

Have shares in the company

In which the company has interests

Latest issues

Show all

Licenses

Public debt by currencies

Show more Hide

Codes

  • TIN
    7702508905
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • IEC
    773601001
  • PSRN
    1037789001315 on 27/11/2003
  • OKPO
    71328785

Issuer's quarterly reports/RAS Reports

2026
I q NTL
2025
I q NTL
II q NTL
III q NTL
IV q NTL
2024
I q NTL
II q NTL
III q NTL
IV q NTL
2023
I q NTL
II q NTL
III q NTL
IV q NTL
2022
I q NTL
II q NTL
III q NTL
IV q NTL
2021
I q NTL
II q NTL
III q NTL
IV q NTL
2020
I q NTL
II q NTL
III q NTL
IV q NTL
2019
I q NTL
II q NTL
III q NTL
IV q NTL
2018
I q NTL
II q NTL
III q NTL
IV q NTL
2017
I q NTL
II q NTL
III q NTL
IV q NTL
2016
I q NTL
II q NTL
III q NTL
IV q NTL
2015
II q NTL
III q NTL
IV q NTL
2011
I q NTL
2010
III q NTL
2009
I q NTL
II q NTL
III q NTL
IV q NTL
2008
I q NTL
II q NTL
III q NTL
IV q NTL
2007
I q NTL
II q NTL
III q NTL
IV q NTL
Show all Hide
Authorization required
You need to request access

Annual reports

2024
IV q NTL
2023
IV q NTL
2022
IV q NTL
2021
IV q NTL
Show all Hide
Authorization required
You need to request access
Registration is required to get access.